vs
Apellis Pharmaceuticals, Inc.（APLS）与ServiceTitan, Inc.（TTAN）财务数据对比。点击上方公司名可切换其他公司
ServiceTitan, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$249.2M vs $199.9M），ServiceTitan, Inc.净利率更高（-15.9% vs -29.5%，领先13.6%），ServiceTitan, Inc.同比增速更快（25.0% vs -5.9%），ServiceTitan, Inc.自由现金流更多（$42.2M vs $-14.3M）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Alphabet Inc.是总部位于美国加利福尼亚州山景城的跨国科技集团控股企业，2015年10月2日通过谷歌重组设立，为谷歌及原谷歌旗下多家子公司的母公司。其两股普通股GOOGL、GOOG均在纳斯达克大盘板块上市，是标普500、纳斯达克100等主流股指的成分股。
APLS vs TTAN — 直观对比
营收规模更大
TTAN
是对方的1.2倍
$199.9M
营收增速更快
TTAN
高出31.0%
-5.9%
净利率更高
TTAN
高出13.6%
-29.5%
自由现金流更多
TTAN
多$56.5M
$-14.3M
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $249.2M |
| 净利润 | $-59.0M | $-39.5M |
| 毛利率 | — | 70.8% |
| 营业利润率 | -25.6% | -16.9% |
| 净利率 | -29.5% | -15.9% |
| 营收同比 | -5.9% | 25.0% |
| 净利润同比 | -62.2% | 14.9% |
| 每股收益（稀释后） | $-0.40 | $-0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTTAN
| Q4 25 | $199.9M | $249.2M | ||
| Q3 25 | $458.6M | $242.1M | ||
| Q2 25 | $178.5M | $215.7M | ||
| Q1 25 | $166.8M | $209.3M | ||
| Q4 24 | $212.5M | $199.3M | ||
| Q3 24 | $196.8M | — | ||
| Q2 24 | $199.7M | $170.3M | ||
| Q1 24 | $172.3M | — |
净利润APLSTTAN
| Q4 25 | $-59.0M | $-39.5M | ||
| Q3 25 | $215.7M | $-32.2M | ||
| Q2 25 | $-42.2M | $-46.4M | ||
| Q1 25 | $-92.2M | $-100.9M | ||
| Q4 24 | $-36.4M | $-46.5M | ||
| Q3 24 | $-57.4M | — | ||
| Q2 24 | $-37.7M | $-56.0M | ||
| Q1 24 | $-66.4M | — |
毛利率APLSTTAN
| Q4 25 | — | 70.8% | ||
| Q3 25 | — | 70.8% | ||
| Q2 25 | — | 68.8% | ||
| Q1 25 | — | 66.0% | ||
| Q4 24 | — | 65.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 62.2% | ||
| Q1 24 | — | — |
营业利润率APLSTTAN
| Q4 25 | -25.6% | -16.9% | ||
| Q3 25 | 48.7% | -14.4% | ||
| Q2 25 | -18.6% | -23.0% | ||
| Q1 25 | -50.0% | -47.7% | ||
| Q4 24 | -12.3% | -22.1% | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | -31.4% | ||
| Q1 24 | -36.0% | — |
净利率APLSTTAN
| Q4 25 | -29.5% | -15.9% | ||
| Q3 25 | 47.0% | -13.3% | ||
| Q2 25 | -23.6% | -21.5% | ||
| Q1 25 | -55.3% | -48.2% | ||
| Q4 24 | -17.1% | -23.3% | ||
| Q3 24 | -29.2% | — | ||
| Q2 24 | -18.9% | -32.9% | ||
| Q1 24 | -38.5% | — |
每股收益（稀释后）APLSTTAN
| Q4 25 | $-0.40 | $-0.42 | ||
| Q3 25 | $1.67 | $-0.35 | ||
| Q2 25 | $-0.33 | $-0.51 | ||
| Q1 25 | $-0.74 | $-3.34 | ||
| Q4 24 | $-0.30 | $-1.74 | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | $-2.02 | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $493.2M |
| 总债务越低越好 | — | $103.6M |
| 股东权益账面价值 | $370.1M | $1.5B |
| 总资产 | $1.1B | $1.8B |
| 负债/权益比越低杠杆越低 | — | 0.07× |
8季度趋势，按日历期对齐
现金及短期投资APLSTTAN
| Q4 25 | $466.2M | $493.2M | ||
| Q3 25 | $479.2M | $471.5M | ||
| Q2 25 | $370.0M | $420.3M | ||
| Q1 25 | $358.4M | $441.8M | ||
| Q4 24 | $411.3M | $133.8M | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | $116.2M | ||
| Q1 24 | $325.9M | — |
总债务APLSTTAN
| Q4 25 | — | $103.6M | ||
| Q3 25 | — | $103.7M | ||
| Q2 25 | — | $103.9M | ||
| Q1 25 | — | $104.0M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSTTAN
| Q4 25 | $370.1M | $1.5B | ||
| Q3 25 | $401.2M | $1.5B | ||
| Q2 25 | $156.3M | $1.5B | ||
| Q1 25 | $164.2M | $1.5B | ||
| Q4 24 | $228.5M | $-576.8M | ||
| Q3 24 | $237.1M | — | ||
| Q2 24 | $264.3M | $-506.0M | ||
| Q1 24 | $266.7M | — |
总资产APLSTTAN
| Q4 25 | $1.1B | $1.8B | ||
| Q3 25 | $1.1B | $1.8B | ||
| Q2 25 | $821.4M | $1.7B | ||
| Q1 25 | $807.3M | $1.8B | ||
| Q4 24 | $885.1M | $1.5B | ||
| Q3 24 | $901.9M | — | ||
| Q2 24 | $904.5M | — | ||
| Q1 24 | $831.9M | — |
负债/权益比APLSTTAN
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $43.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $42.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 16.9% |
| 资本支出强度资本支出/营收 | 0.1% | 0.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSTTAN
| Q4 25 | $-14.2M | $43.8M | ||
| Q3 25 | $108.5M | $40.3M | ||
| Q2 25 | $4.4M | $-14.6M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | $15.5M | ||
| Q3 24 | $34.1M | — | ||
| Q2 24 | $-8.3M | $-19.2M | ||
| Q1 24 | $-133.0M | — |
自由现金流APLSTTAN
| Q4 25 | $-14.3M | $42.2M | ||
| Q3 25 | $108.3M | $39.2M | ||
| Q2 25 | $4.4M | $-15.9M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | $14.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | $-19.9M | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSTTAN
| Q4 25 | -7.1% | 16.9% | ||
| Q3 25 | 23.6% | 16.2% | ||
| Q2 25 | 2.5% | -7.4% | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | 7.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | -11.7% | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSTTAN
| Q4 25 | 0.1% | 0.6% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | 0.2% | — |
现金转化率APLSTTAN
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TTAN
| Subscription Revenue | $182.8M | 73% |
| Usage Revenue | $56.8M | 23% |
| Professional Services And Other Revenue | $9.6M | 4% |
